3 days Ago By ABMN Staff
StockNews.com cut shares of Boston Scientific ( NYSE:BSX – Free Report ) from a buy rating to a hold rating in a research report sent to investors on Friday morning. Other equities analysts have also issued reports about the stock.
Raymond James increased their price target on shares of Boston Scientific from $91.00 to $94.00 and gave the company a strong-buy rating in a research note on Wednesday, September 4th.
Royal Bank of Canada reiterated an outperform rating and issued a $85.00 price target on shares of Boston Scientific in a research note on Thursday, July 25th. Canaccord Genuity Group increased their price target on shares of Boston Scientific from $83.
00 to $88.00 and gave the company a buy rating in a research note on Thursday, July 25th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Boston Scientific from $73.
00 to $78.00 and gave the company a hold rating in a research note on Thursday, July 25th. Finally, Robert W.
Baird increased their price target on shares of Boston Scientific from $90.00 to $91.00 and gave the company an outperform rating in a research note on Thursday, July 25th.
Three equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Boston Scientific presently has an average rating of Moderate Buy and a consensus target price of $85.
38. View Our Latest Stock Analysis on BSX Boston Scientific Stock Down 0.6 % Boston Scientific ( NYSE:BSX – Get Free Report ) last released its earnings results on Wednesday, July 24th.
The medical equipment provider reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.
04. The firm had revenue of $4.12 billion for the quarter, compared to analyst estimates of $4.
02 billion. Boston Scientific had a net margin of 12.00% and a return on equity of 16.
59%. The business’s quarterly revenue was up 14.5% compared to the same quarter last year.
During the same period in the prior year, the firm earned $0.53 earnings per share. On average, equities research analysts anticipate that Boston Scientific will post 2.
4 EPS for the current fiscal year. Insider Buying and Selling In related news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $74.
12, for a total transaction of $517,579.96. Following the completion of the sale, the executive vice president now directly owns 40,188 shares of the company’s stock, valued at $2,978,734.
56. The sale was disclosed in a filing with the SEC, which is available through the SEC website . Insiders sold a total of 20,949 shares of company stock valued at $1,627,877 over the last three months.
0.50% of the stock is currently owned by company insiders. Institutional Investors Weigh In On Boston Scientific Hedge funds have recently modified their holdings of the stock.
Newbridge Financial Services Group Inc. raised its position in Boston Scientific by 2,100.5% in the second quarter.
Newbridge Financial Services Group Inc. now owns 9,132 shares of the medical equipment provider’s stock worth $703,000 after acquiring an additional 8,717 shares in the last quarter. Sanctuary Advisors LLC purchased a new position in Boston Scientific in the second quarter worth $5,349,000.
Brown Financial Advisors purchased a new position in Boston Scientific in the second quarter worth $1,423,000. RiverFront Investment Group LLC purchased a new position in Boston Scientific in the second quarter worth $222,000. Finally, Cetera Investment Advisers raised its position in Boston Scientific by 2.
9% in the second quarter. Cetera Investment Advisers now owns 295,984 shares of the medical equipment provider’s stock worth $22,794,000 after acquiring an additional 8,399 shares in the last quarter. 89.
07% of the stock is owned by institutional investors and hedge funds. About Boston Scientific ( Get Free Report ) Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular.
The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. Featured Stories Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter .
.
